InvestWiserRespiratorius AB
RESP · Nasdaq Stockholm · Healthcare
2.11SEK
−2.8%last day
Price as of 1 October 2026
Performance
1 month
−6.2%
1 year
−14.6%
3 years, per year
−54.4%
5 years, per year
−54.0%
Largest fall, 3 years
−97.8%
Below the peak now
−99.3%
Volatility, 1 year
98.5%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
0.6
Dividend yield
0.0%
Return on equity
−24.3%
Net margin
–
Market value
2 m USD
Quality, value and trend
Where Respiratorius stands against every Nordic stock today. 100 is best.
59
Profitability and a sound balance sheet over time. Better than 59% of Nordic stocks.
25
The price measured against earnings, assets and cash flow. Better than 25% of Nordic stocks.
46
The price development over the past year. Better than 46% of Nordic stocks.
35
Quality, value and trend together. Better than 35% of Nordic stocks.
About Respiratorius
Respiratorius AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK.
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis